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Life expectancy in HIV-positive persons in
Switzerland: matched comparison with
general population
Aysel Guelera,M, Andre´ Mosera,b,M, Alexandra Calmyc,
Huldrych F. Gu¨nthardd,e, Enos Bernasconif, Hansjakob Furrerg,
Christoph A. Fuxh, Manuel Battegayi, Matthias Cavassinij,
Pietro Vernazzak, Marcel Zwahlena, Matthias Eggera,l,
for the Swiss HIV Cohort Study, Swiss National Cohort
Objectives: To estimate life expectancy over 25 years in HIV-positive people and to
compare their life expectancy with recent estimates for the general population, by
education.
Methods: Patients aged 20 years or older enrolled in the Swiss HIV Cohort Study 1988–
2013 were eligible. Patients alive in 2001 were matched to up to 100 Swiss residents, by
sex, year of birth, and education. Life expectancy at age 20 was estimated for
monotherapy (1988–1991), dual therapy (1992–1995), early combination antiretro-
viral therapy (cART, 1996–1998), later cART (1999–2005) and recent cART (2006–
2013) eras. Parametric survival regression was used to model life expectancy.
Results: In all, 16 532 HIV-positive patients and 927 583 residents were included. Life
expectancy at age 20 of HIV-positive individuals increased from 11.8 years [95%
confidence interval (CI) 11.2–12.5] in the monotherapy era to 54.9 years (95% CI
51.2–59.6) in the most recent cART era. Differences in life expectancy across educational
levels emerged with cART. In the most recent cART period, life expectancy at age 20 years
was 52.7 years (95% CI 46.4–60.1) with compulsory education, compared to 60.0 years
(95% CI 53.4–67.8) with higher education. Estimates for the general population were
61.5 and 65.6 years, respectively. Male sex, smoking, injection drug use, and low CD4þ
cell counts at enrolment were also independently associated with mortality.
Conclusion: In Switzerland, educational inequalities in life expectancy were larger
among HIV-infected persons than in the general population. Highly educated HIV-
positive people have an estimated life expectancy similar to Swiss residents with
compulsory education. Earlier start of cART and effective smoking-cessation programs
could improve HIV-positive life expectancy further and reduce inequalities.
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Introduction
Estimates of life expectancy are of obvious importance
to individuals who are HIV-positive, and important to
monitor and predict the progress of the HIV/AIDS
epidemic and to plan health services. Several studies
have examined life expectancy in HIV-positive people
in the era of combination antiretroviral therapy (cART)
[1–6]. In recent years, the question has arisen whether
in some settings life expectancy of HIV-positive people
may have reached that observed in the general
population [7,8]. A recent review expressed life
expectancy at age 20 years of HIV-positive individuals
on cART as a percentage of life expectancy in the
general or HIV-negative population, and found that
percentages ranged from 60% in Rwanda to 90% in
Canada [9].
Comparisons of life expectancy in HIV-positive people
and the general population are fraught with difficulties,
particularly in high-income countries. People living
with HIV have lifestyles and behaviors that may reduce
their life expectancy, regardless of their HIV infection.
For example, HIV-positive people have higher rates
of smoking, alcohol, and recreational drug use, and
higher rates of other sexually transmitted co-infections
and hepatitis C [10–14]. Ideally, lifestyle and behaviors
would be measured comprehensively both in the
HIV-positive and in the general population, using
standardized methods. However, such data are not
available from the vital registration systems used to
estimate life expectancy in the general population.
Matching HIV-positive people to members of the
general population for variables that are associated with
lifestyles and behaviors is one way to address this issue.
The level of education is associated with lifestyles both
in HIV-positive people and in the general population
[15,16], and the association of education with life
expectancy is well documented in many general
populations [17–19].
The Swiss HIV Cohort Study (SHCS) is a nationwide,
prospective cohort study of HIV-infected patients [20].
Established in 1988, the SHCS is one of the longest-
running HIV cohort study worldwide. Level of education
is assessed in categories that match those used by the Swiss
National Cohort (SNC) [21], a census-based longitudinal
study of mortality in Switzerland. We analyzed life
expectancy in the SHCS 1988–2013 and compared life
expectancy across levels of education with life expectancy
in the general Swiss population, using the data from
the SNC.
Materials and methods
Data sources
The SHCS has been described in detail elsewhere
[20,22]. Adults aged 16 years or older are followed up at
University outpatient clinics, Cantonal hospitals, and
private practices. Clinical stage is classified according to
the clinical criteria of the Centers for Disease Control and
Prevention (CDC) [23]. Socio-demographic, behavioral,
and clinical parameters are collected at enrolment and
then in 6-monthly intervals. CD4þ cell counts, HIV-1
viral load (determined with Roche Amplicor HIV-1
Monitor Assay), and other laboratory results are collected
at 3-monthly follow-up visits. Antiretroviral treatment
is documented at enrolment and follow-up visits. All
participants aged 20 years and older enrolled in the SHCS
between 1 January 1988 and 31 December 2013 were
eligible for the present analysis.
The SNC is a longitudinal study of mortality in the
resident population of Switzerland, based on the 1990 and
2000 national censuses [21]. In brief, deterministic and
probabilistic record linkage [24] was performed using the
Generalized Record Linkage System [25] to link census
records to a death record or an emigration record, based
on a set of key variables that are available in all data sets
(sex, date of birth, place of residence, marital status,
religion, nationality, profession, and, if applicable, date
of birth of partner and date of birth of children).
Enumeration in the Swiss census was near-complete: for
the 2000 census, coverage is estimated at 98.6% [26]. For
the present study, analyses were restricted to residents
aged 20 years or older. We drew a random sample of up to
100 individuals from census 2000 for each patient
enrolled in the SHCS and alive on 1 January 2001,
matched for sex, year of birth, and level of education.
Comparisons and definitions
The two datasets allowed consistent definitions of
educational level as higher education, vocational training,
or compulsory school. We further examined life
expectancy by period of enrolment into the study,
defined by the type of ART available during the period:
the monotherapy era (1988–1991), dual therapy era
(1992–1995), early cART era (1996–1998), later cART
era (1999–2005), and recent cART era (2006–2013).
Estimates of life expectancy were calculated for each
treatment era by educational level, main source of
income, HIV transmission group, history of injection
drug use (IDU), smoking status, and presentation at
enrolment. Late presentation was defined as a person with
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HIV first presenting for care with a CD4þ cell count less
than 350 cells/ml or with an AIDS-defining event [27].
Presentation with advanced HIV disease was defined
as presentation with a CD4þ cell count less than
200 cells/ml or with AIDS: patients presenting with
advanced disease are a subgroup of late presenters.
Smoking status was classified as never, former, or current.
Individuals who had used injection drugs within 6 months
of registration were classified as current IDU. Former
IDU was defined as other documented IDU prior to
registration. We defined transmission groups as hetero-
sexual, MSM, IDU, and other/unknown (including
mother to child transmission and blood transfusions). We
defined exposure to hepatitis C virus (HCV) as positive
anti-HCVor HCV-RNA tests, and chronic hepatitis B as
positive HBs-antigen or HBV-DNA tests.
Statistical analysis
We used parametric survival regression to model life
expectancy. Estimates of life expectancy were calculated
assuming a Gompertz distribution [28,29], overall and by
education and other subgroups with at least 100 patients
and at least 20 deaths. We used univariable and
multivariable Cox models to examine the association
between education and mortality, adjusting for sex,
injection drug use (never, former, current), smoking
(never, former, current), CD4þ cell count at enrolment
(<200, 200–349, 350 cells/ml), and clinical stage
(CDC clinical stage C versus A/B). In all models, age
was the underlying time scale. Observation time was
measured from enrolment to the time the outcome
occurred or the last date information was recorded. In the
matched general population sample, we modeled age at
death or age at 31 December 2013, with age at 1 January
2001 as delayed entry information. In sensitivity analyses,
we excluded patients with a history of current or past
IDU. Data were analyzed in Stata (Stata Corp., College
Station, Texas, USA, version 13.1) and R (R Foundation
for Statistical Computing, Vienna, Austria, version 3.0.2).
Results are presented as estimates of life expectancy and
hazard ratios, with 95% confidence intervals (CIs).
Results
In all, 17 169 patients were enrolled in the SHCS, of
whom 637 (3.7%) patients were excluded: 155 were aged
less than 20 years, one patient had an erroneous
enrolment date, and 481 patients had no follow-up data
recorded. In all, 16 532 patients were thus included:
11 916 (72.1%) were men, 11 304 (68.4%) were treat-
ment-naive at enrolment, and 4707 (28.5%) had a history
of current or past IDU. Median follow-up was 6.30 years
[interquartile range (IQR) 2.5–13.0 years], median age
was 35 years (IQR 29–42 years), and the median CD4þ
cell count at enrolment was 332 cells/ml (IQR 167–536).
The matched general population sample from the SNC
included 927 583 individuals aged 20 years or older on
1 January 2001.
Characteristics of HIV-positive patients by
therapy era and education
Figure 1 shows the introduction of monotherapy and
combination therapies over time. Median age increased
from 31 years in the monotherapy era to 38 years in the
recent cARTera (Table 1). Data on education and source of
income was missing in most patients in the monotherapy
era, but was near-complete in more recent years, showing
an increase in the proportion of study participants with
higher education, and an increase in patients in work.
MSM were the most common transmission group in all
eras except for the monotherapy era, when patients with a
historyof IDU dominated.The proportion of patientswith
a history of current or past IDU declined, from 50.2% in
the monotherapy era to 9.8% in the most recent cARTera.
Smoking was not assessed consistently in the earlier
periods, but appears to have declined in the most recent
cART era. The proportion of participants from sub-
SaharanAfrica increased from 2.1% in themonotherapyera
to 16.0% in the most recent cART era. Compared to
patients with compulsory school only, patients with higher
education were more likely to be MSM, to be working in
higheror middle management, and less likely to be smokers
or IDU (Supplemental Table S1, http://links.lww.com/
QAD/B13).
Table 2 shows the clinical and laboratory characteristics of
the 11 304 participants who were treatment-naive at
enrolment. The median CD4þ cell count at enrolment
was higher in the monotherapy than in the dual therapy
era, and increased thereafter, to 369 cells/ml in the most
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Fig. 1. Introduction of monotherapy, dual therapy, and
triple combination antiretroviral therapy (cART) in the Swiss
HIV cohort (1988–2013).
recent cARTera. The prevalence of exposure to hepatitis
C and of chronic hepatitis B declined as testing expanded
during the study period. Patients with higher education
had slightly higher CD4þ cell counts at enrolment, and
were less likely to present with advanced disease than
patients with compulsory education. They were also less
likely to have been exposed to hepatitis C or to have
chronic hepatitis B (Supplementary Table S2, http://
links.lww.com/QAD/B13).
Life expectancy in HIV-positive people
In all, 4579 deaths were recorded during the study period.
The proportion of patients who died during follow-up
declined from 65.1% (2489/3821) among patients
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Table 1. Socio-demographic characteristics of patients aged 20 years or older at enrolment in the Swiss HIV Cohort Study, by treatment eras.
Monotherapy
(1988–1991)
Dual therapy
(1992–1995)
Early cART
(1996–1998)
Later cART
(1999–2005)
Recent cART
(2006–2013)
No. of participants 3821 (23.1) 2392 (14.5) 2335 (14.1) 3727 (22.5) 4257 (25.8)
No. of women 1027 (22.3) 607 (13.2) 722 (15.6) 1192 (25.8) 1068 (23.1)
Median (IQR) age (years) 31 (27–37) 33 (28–39) 35 (30–41) 37 (31–43) 38 (31–46)
Education
Higher education 236 (6.2) 312 (13.0) 436 (18.7) 827 (22.2) 1374 (32.3)
Vocational training 792 (20.7) 1067 (44.6) 1229 (52.6) 1773 (47.6) 1932 (45.4)
Compulsory school 441 (11.5) 576 (24.1) 650 (27.8) 1112 (29.8) 926 (21.8)
Other/unknown 2352 (61.6) 437 (18.3) 20 (0.9) 15 (0.4) 25 (0.6)
Main source of income
Work 2 (0.1) 703 (29.4) 1270 (54.4) 2042 (54.8) 2686 (63.1)
Welfare benefits 0 391 (16.4) 807 (34.6) 1252 (33.6) 1027 (24.1)
Family support 0 94 (3.9) 224 (9.6) 393 (10.5) 494 (11.6)
Other/unknown 3819 (99.9) 1204 (50.3) 34 (1.5) 40 (1.1) 50 (1.2)
HIV transmission group
MSM 1191 (31.2) 857 (35.8) 750 (32.1) 1256 (33.7) 2163 (50.8)
Heterosexual contact 783 (20.5) 615 (25.7) 873 (37.4) 1719 (46.1) 1607 (37.8)
Injection drug user 1744 (45.6) 835 (34.9) 618 (26.5) 604 (16.2) 276 (6.5)
Other/unknown 103 (2.7) 85 (3.6) 94 (4.0) 148 (4.0) 211 (5.0)
Injection drug use
Never 1903 (49.8) 1453 (60.7) 1616 (69.2) 3015 (80.9) 3838 (90.2)
Former 1532 (40.1) 628 (26.3) 485 (20.8) 441 (11.8) 396 (9.3)
Current 386 (10.1) 311 (13.0) 234 (10.0) 271 (7.3) 23 (0.5)
Smoking
Never 188 (4.9) 318 (13.3) 550 (23.6) 1362 (36.5) 1815 (42.6)
Former 110 (2.9) 145 (6.1) 198 (8.5) 504 (13.5) 664 (15.6)
Current 708 (18.5) 769 (32.2) 1145 (49.0) 1790 (48.0) 1765 (41.5)
Unknown 2815 (73.7) 1160 (48.5) 442 (18.9) 71 (1.9) 13 (0.3)
Region of origin
Switzerland and North-West Europe 3266 (85.5) 1905 (79.6) 1746 (74.8) 2403 (64.5) 2579 (60.6)
Southern Europe 319 (8.4) 253 (10.6) 189 (8.1) 308 (8.3) 320 (7.5)
Sub-Saharan Africa 79 (2.1) 96 (4.0) 197 (8.4) 565 (15.2) 680 (16.0)
Latin America 39 (1.0) 45 (1.9) 51 (2.2) 112 (3.0) 222 (5.2)
Asia, Eastern Europe 60 (1.6) 57 (2.4) 82 (3.5) 220 (5.9) 326 (7.7)
Other/unknown 58 (1.5) 36 (1.5) 70 (3.0) 119 (3.2) 130 (3.1)
Analysis based on 16 532 individuals. IQR, interquartile range [numbers (percentages) are shown unless otherwise stated].
Table 2. Clinical and laboratory characteristics patients who were treatment-naı¨ve at enrolment into the Swiss HIV Cohort Study, by treatment
eras.
Characteristics
Monotherapy
(1988–1991)
Dual therapy
(1992–1995)
Early cART
(1996–1998)
Later cART
(1999–2005)
Recent cART
(2006–2013)
Number of patients 3308 1926 1267 2319 2484
Median CD4þ cell count (IQR),
cells/ml
360 (170–590) 290 (120–517) 334 (169–534) 351 (194–536) 369 (223–541)
Median HIV-RNA log10 (IQR),
copies/ml
  4.5 (3.8–5.0) 4.6 (3.9–5.1) 4.6 (3.9–5.1)
Exposure to hepatitis C 55.6% (79/142) 42.8% (264/617) 37.2% (371/998) 19.4% (413/2132) 6.3% (142/2270)
Chronic hepatitis B 8.7% (105/1208) 7.8% (89/1134) 5.5% (62/1134) 6.9% (154/2243) 5.0% (117/2341)
Late presentation 53.0% (1745/3295) 59.9% (1154/1926) 55.6% (705/1267) 54.3% (1258/2319) 49.5% (1230/2484)
Presentation with advanced
HIV disease
33.4% (1089/3264) 40.3% (775/1922) 32.9% (417/1267) 29.5% (684/2319) 23.7% (588/2484)
Presentation with AIDS 21.6% (714/3308) 20.9% (403/1926) 14.7% (186/1267) 12.4% (287/2319) 8.2% (203/2484)
Analysis based on of 11 304 individuals. cART, combination antiretroviral therapy; IQR, interquartile range.
enrolled in the monotherapy era to 2.4% (101/4257)
among those enrolled in the most recent cART era.
Table 3 presents estimates of life expectancy at age
20 years across the five treatment periods, by socio-
demographic and clinical characteristics at enrolment.
Overall, life expectancy at age 20 years of HIV-positive
individuals enrolled in the SHCS increased from
11.8 years (95% CI 11.2–12.5) in the monotherapy era
to 54.9 years (95% CI 51.2–59.6) in the most recent
cART era (Fig. 2).
Differences in life expectancy across educational level
emerged with the introduction of cART (Fig. 3). For
example, in the most recent cART era, life expectancy
at age 20 years was 52.7 years among participants with
compulsory education, compared to 60.0 years among
those with higher education. In the same period,
estimated life expectancy was 35.8 years among patients
who contracted HIV through IDU, but above 50 years for
the other transmission groups; it was 49.4 years in current
smokers compared to 59.0 years in never smokers. Life
expectancy was also influenced by presentation at
enrolment. For example, in the most recent cART
period, life expectancy at age 20 was 47.6 years among
patients presenting with a CD4þ cell count below
200 cells/ml, and 46.3 years among those presenting with
AIDS (Table 3).
The educational gradient in life expectancy at age 20 years
was attenuated when excluding patients with a history of
current or past IDU but patients with higher education
continued to have a higher life expectancy than those
with less education (Supplementary Table S3, http://
links.lww.com/QAD/B13). Similarly, in Cox regression
models including patients enrolled 1992 to 2013, lower
educational level continued to be associated with
mortality after adjustment for history of IDU, smoking,
CD4þ cell count at enrolment and sex (Table 4).
Comparisons with the general population
Figure 2 and Figure 3 present estimates of life expectancy
at age 20 years during periods 2001–2005 and 2006–
2013 for the matched sample from the general Swiss
population. Whereas life expectancy increased substan-
tially in the HIV-positive population, only slight
increases were observed in the general population, from
62.3 to 63.0 years overall, and from 61.1 to 61.5 years
in people with compulsory education, from 61.2 to
62.2 years in those with vocational training and from
65.4 to 65.6 years in people with higher education. In the
most recent cART period, HIV-positive people con-
tinued to have an estimated life expectancy that was lower
than their peers from the general population. It was
91.5% (95% CI 84.6–98.4%) of the matched general
population for patients with higher education, 84.5%
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Table 3. Life expectancy at age 20 years in the Swiss HIV Cohort Study, by treatment era.
Life expectancy (95% CI)
Monotherapy
(1988–1991)
Dual therapy
(1992–1995)
Early cART
(1996–1998)
Later cART
(1999–2005)
Recent cART
(2006–2013)
Overall life expectancy 11.8 (11.2–12.5) 20.8 (19.4–22.2) 44.7 (42.2–47.3) 50.8 (48.5–53.3) 54.9 (51.2–59.6)
Education
Higher education – 26.7 (22.2–31.6) 53.0 (46.9–59.0) 58.2 (53.4–63.2) 60.0 (53.4–67.8)
Vocational training – 25.3 (23.0–27.7) 44.4 (41.4–47.7) 49.2 (46.5–52.1) 52.6 (48.3–57.9)
Compulsory school – 24.3 (21.3–27.5) 38.9 (35.1–43.0) 46.5 (43.1–50.3) 52.7 (46.4–60.1)
Main source of income
Work – 32.8 (29.2–36.5) 55.0 (50.9–58.9) 63.9 (59.3–68.4) 62.9 (56.2–70.9)
Welfare benefits – 15.8 (13.6–18.4) 31.5 (29.0–34.1) 39.4 (36.9–42.0) 48.0 (43.4–53.0)
HIV transmission group
MSM 8.9 (8.1–9.8) 22.9 (20.5–25.4) 52.7 (48.6–57.1) 57.3 (53.5–61.5) 56.8 (51.8–63.6)
Heterosexual contact 15.3 (13.7–17.21) 29.6 (26.1–33.3) 49.5 (45.8–53.6) 53.1 (50.2–56.2) 56.7 (51.7–62.8)
Injection drug use 12.4 (11.5–13.3) 15.7 (14.2–17.4) 27.3 (25.3–29.5) 31.3 (28.8–33.4) 35.8 (30.6–41.5)
Injection drug use
Never 11.3 (10.4–12.2) 25.1 (23.1–27.2) 51.9 (49.0–55.1) 54.6 (52.2–57.1) 57.2 (53.1–62.5)
Former 12.2 (11.4–13.1) 16.9 (15.0–18.9) 29.9 (27.4–32.5) 33.5 (30.9–36.3) 39.6 (34.4–45.1)
Current 12.2 (10.6–14.0) 15.2 (12.9–17.7) 24.7 (21.7–27.9) 29.0 (25.8–32.4) 
Smoking
Never – – – 65.2 (60.1–70.6) 59.0 (53.5–65.7)
Former – – – 56.4 (51.2–62.1) 54.6 (48.2–61.8)
Current – – – 42.8 (40.7–45.2) 49.4 (45.2–54.6)
Presentation at enrolmentM
CD4þ cell count <200 cells/ml 3.2 (2.9–3.6) 6.5 (5.5–7.6) 35.1 (30.2–40.3) 46.7 (42.6–51.2) 47.6 (41.9–54.3)
200–349 cells/ml 11.2 (9.9–12.5) 26.0 (21.7–30.6) 48.0 (40.3–55.6) 50.2 (45.0–55.9) 54.0 (47.0–63.0)
350 cells/ml 25.2 (23.5–27.1) 44.5 (40.2–48.6) 59.9 (52.8–66.0) 53.0 (48.7–57.9) 63.9 (54.8–76.0)
Late presentation 6.1 (5.6–6.7) 12.1 (10.6–13.6) 41.1 (36.8–45.5) 48.7 (45.5–52.3) 53.2 (48.2–59.5)
Presentation with advanced HIV disease 3.5 (3.2–3.9) 7.3 (6.2–8.4) 36.0 (31.2–41.0) 46.5 (42.7–50.8) 49.1 (43.5–55.5)
Presentation with AIDS 2.4 (2.2–2.7) 4.4 (3.7–5.2) 29.1 (23.4–35.3) 42.1 (37.1–47.7) 46.3 (38.4–54.9)
Results from Gompertz parametric survival regression models. Univariate analyses based on 16 532 patients. CI, confidence interval. –, not
estimated due to large amount of missing data or small number of patients and deaths.
(95% CI 78.8–90.3%) for patients with vocational
training, and 85.6% (95% CI 76.7–94.6%) for patients
with compulsory education. Life expectancy in highly
educated patients was similar to the life expectancy of
individuals from the general population with compulsory
education only.
Discussion
We estimated life expectancy at age 20 years in HIV-
positive patients enrolled in the SHCS over 25 years and
during five treatment periods, from the monotherapy
era end of the 1980s to the recent years of potent cART.
Life expectancy increased, with the most substantial
increase observed when cART was first introduced
(1996–1998). Life expectancy continued to increase
thereafter and was highest in the most recent cART
period, with greater life expectancy among those
with higher education compared to those with
compulsory education only. The comparison with
the Swiss population showed that in the most recent
cART period, life expectancy continued to be lower
in HIV-positive people overall, and lower within each
educational category. Of note, HIV-positive people
with higher education had an estimated life expectancy
similar to individuals from the general population with
compulsory education.
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Fig. 2. Life expectancy at age 20 years in patients enrolled in the Swiss HIV Cohort Study, from monotherapy (1988–1991) to
recent combination ART era (2006–2013), and in a matched sample from the general Swiss population (2001–2013). ART,
antiretroviral therapy.
Education is frequently used as an indicator of socio-
economic position [30]. It is usually completed in early
adulthood and therefore suitable for analyses of life
expectancy in young adults. Educational level will act as a
distal cause, by influencing lifestyles and behaviors,
including health-seeking behaviors, which, in turn, will
translate into proximal, direct causes, for example, IDU or
late presentation to care. The level of education attained
reflects both early life and family circumstances and adult
resources, including material resources, knowledge, and
cognitive functioning. The well educated will be more
receptive to health education messages, and better able to
communicate with and access health services [30]. In our
study, lower education was associated with IDU and
smoking, but not with late presentation to care. An
analysis of the Danish HIV Cohort Study also showed no
association between educational attainment and late
presentation [31]. In contrast, a pooled analysis of
European HIV cohorts found that presentation with
advanced HIV disease was more common in the less
educated [32].
Strengths and weaknesses
To our knowledge, this is the first study of life expectancy
in HIV-positive people spanning 25 years, and the first
comparison of HIV-positive life expectancy with the
general population that was matched for educational
level. Initiated in 1988, the SHCS is one of the longest
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Fig. 3. Life expectancy at age 20 years by education in patients enrolled in the Swiss HIV Cohort Study, from dual therapy
(1992–1995) to recent combination ART era (2006–2013), and in a matched sample from the general Swiss population (2001–
2013). ART, antiretroviral therapy.
running HIV cohort studies worldwide. The study
collects detailed socio-demographic, behavioral, clinical,
and laboratory data, and has national coverage: com-
parisons with official AIDS notifications and drug sales
data show that approximately 69% of all persons living
with HIV/AIDS in Switzerland participate in the SHCS,
and that 75% of antiretroviral drug prescriptions relate
to study participants [20,33]. The rich data allowed us to
estimate life expectancy in different antiretroviral treat-
ment periods, by education and other subgroups defined
by socio-economic, behavioral, and clinical status. The
comparison with a random sample of over 1 million Swiss
residents, which was matched for education and therefore
to some extent for lifestyle and behaviors, is another
strength of the present analysis.
We acknowledge that matching for education may
achieve groups that are reasonably comparable with
respect to some risk factors, for example, smoking, but
not for risk factors or comorbidities associated with sexual
orientations and behaviors, illicit drug use, or ART. Our
analysis has other limitations. Some variables of interest,
for example, smoking, were not collected consistently
in the earlier years; the collection of others, for example,
occupational status, was abandoned in later years, and
other variables, for example, alcohol intake, were
introduced only recently and therefore not used in the
present analyses. Data collection on illicit drug use was
introduced in 2007, and annual syphilis testing was
abandoned in 1998 and re-introduced in 2004. Of note,
syphilis was frequent among MSM and persons reporting
casual sexual partners [34]. Similarly, data on some
cardiovascular comorbidities were not collected before
2000, and data on others were collected only from 2008
onwards. In a Danish study, the higher prevalence of
comorbidities explained a substantial proportion of the
excess mortality observed in the HIV-positive population
compared to the general population [35]. The number of
HIV-positive people included in the analysis was large
overall, but small in some subgroups, for example, for
migrant groups, or for patients with chronic hepatitis,
which precluded the calculation of meaningful estimates
of life expectancy. Finally, although the coverage of the
SHCS is national [20,33], it is unlikely to be fully
representative of all patients living with HIV/AIDS
in Switzerland.
Results in context with other studies
Several studies have estimated life expectancy in HIV-
positive people living in Europe or the United States of
America [1–5,36]. However, only one analysis, from the
Danish HIV Cohort Study, included a matched
comparison group from the general population, which
was matched for place of residence [5]. Like education,
the neighborhood of residence is a powerful measure
of socio-economic position, but matching in the Danish
study was possible only at the level of large municipalities
[5]. In Switzerland, life expectancy is considerably
higher in people living in affluent neighborhoods than
in neighborhoods of low socio-economic position [37],
and the place of residence also matters in HIV infection
[38]. Late presentation was more common and
virologic response to cART less common in HIV-
positive individuals living in neighborhoods of lower
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Table 4. Determinants of mortality in the Swiss HIV Cohort Study (1992–2013).
Univariable analysis Multivariable analysis
Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
Sex <0.001 0.003
Male vs. female 1.35 (1.21–1.51) 1.26 (1.08–1.46)
Education <0.001 0.04
Compulsory school (reference) 1 1
Vocational training 0.89 (0.80–0.99) 0.90 (0.78–1.05)
Higher education 0.68 (0.59–0.79) 0.76 (0.62–0.94)
Injection drug use <0.001 <0.001
Never (reference) 1 1
Former 2.43 (2.17–2.73) 2.95 (2.51–3.48)
Current 2.88 (2.50–3.33) 4.06 (3.31–4.99)
Smoking <0.001 <0.001
Former (reference) 1 1
Never 0.72 (0.56–0.92) 0.87 (0.67–1.11)
Current 2.37 (1.91–2.94) 1.91 (1.53–2.38)
CD4þ cell count (cells/ml) <0.001 <0.001
<200 cells/ml (reference) 1 1
200–349 cells/ml 0.52 (0.47–0.59) 0.76 (0.64–0.90)
350 cells/ml 0.35 (0.31–0.39) 0.71 (0.60–0.82)
CDC clinical stage C <0.001 0.06
Stage C vs. stage A, B 2.33 (2.09–2.59) 1.18 (0.99–1.41)
P value from Wald test for overall association. Results from Cox proportional-hazard models stratified by treatment era (dual therapy, early cART,
later cART, recent cART). The monotherapy era was excluded due to missing data on educational attainment. Univariable analysis based on 12 214
patients, after exclusion of 497 patients with unknown educational attainment. Multivariable analysis based on 10 863 patients, after exclusion of a
further 1351 patients with missing values in other variables. CDC, Centers for Disease Control and Prevention; CI, confidence interval.
socio-economic position, but there was no clear
association between neighborhood and mortality [38].
As expected, life expectancy was higher among those
who never injected drugs compared to ever users, among
never smokers compared to former and current smokers,
and among those who presented late compared to
those who did not, confirming the results from previous
studies [1–5,36]. In line with a recent analysis from the
ART Cohort Collaboration [39], current smoking was
associated with a substantially lower life expectancy: in
the most recent cART era, the difference in life
expectancy between current and never smokers was
almost 10 years. Our results support the notion that
HIV-positive smokers on successful cART may lose
more life-years to smoking than to their HIV infection
[39].
Implications for clinicians or policymakers
Our study has important implications for counseling
Swiss HIV-positive patients on their long-term prognosis,
and our estimates may be relevant to other high-income
countries that provide universal access to ART. Our
results are also relevant to social policy, for example, in the
context of life insurance. Differences in life expectancy
were of the same order of magnitude as the differences
observed between groups of individuals with different
levels of education from the general population, which
lends further support to the notion that HIV-positive
people should be granted access to life cover, at
reasonable rates [40,41]. Unfortunately, access to life
insurance continues to be limited for some HIV-positive
individuals, either because they are rejected by providers
based on the HIV infection, or because premiums are
prohibitively high. Finally, our study suggests that life
expectancy among HIV-positive persons could be further
improved and educational inequalities reduced by earlier
start of cART, effective smoking-cessation programs
tailored to the HIV-positive population, and early
treatment of chronic hepatitis C and B infections, before
liver fibrosis develops [42].
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